Do analysts recommend PALI or RFAI?

Palisade Bio currently has a consensus target price of $9.00, suggesting a potential upside of 320.56%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, PALI or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Palisade Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palisade Bio $250K 1,491.75 -$16.78M -$1.01 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Is PALI or RFAI more profitable?

RF Acquisition Corp II's return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.86% -34.89% RF Acquisition Corp II N/A N/A N/A

Does the media prefer PALI or RFAI?

In the previous week, Palisade Bio had 12 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 15 mentions for Palisade Bio and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Palisade Bio's score of 0.48 indicating that RF Acquisition Corp II is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RF Acquisition Corp II 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RFAI or ZNTL?

Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 89.61%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Zentalis Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher earnings and valuation, RFAI or ZNTL?

RF Acquisition Corp II has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A Zentalis Pharmaceuticals $67.43M 3.78 -$137.06M -$1.95 N/A

Is RFAI or ZNTL more profitable?

RF Acquisition Corp II's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets RF Acquisition Corp II N/A N/A N/A Zentalis Pharmaceuticals N/A -64.23% -48.16%

Does the media favor RFAI or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 16 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 19 mentions for Zentalis Pharmaceuticals and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Zentalis Pharmaceuticals' score of 0.27 indicating that RF Acquisition Corp II is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RF Acquisition Corp II 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer IKT or RFAI?

Inhibikase Therapeutics presently has a consensus target price of $5.40, indicating a potential upside of 124.07%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.00 RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, IKT or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Inhibikase Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibikase Therapeutics $260K 1,293.43 -$48.26M -$0.43 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Is IKT or RFAI more profitable?

RF Acquisition Corp II's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -44.00% -41.90% RF Acquisition Corp II N/A N/A N/A

Does the media prefer IKT or RFAI?

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 5 mentions for Inhibikase Therapeutics and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Inhibikase Therapeutics' score of -0.02 indicating that RF Acquisition Corp II is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RF Acquisition Corp II 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VNDA or RFAI?

Vanda Pharmaceuticals currently has a consensus price target of $13.70, indicating a potential upside of 162.45%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Vanda Pharmaceuticals is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, VNDA or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Vanda Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vanda Pharmaceuticals $216.10M 1.46 -$220.47M -$4.63 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Does the media prefer VNDA or RFAI?

In the previous week, Vanda Pharmaceuticals had 14 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 17 mentions for Vanda Pharmaceuticals and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Vanda Pharmaceuticals' score of -0.09 indicating that RF Acquisition Corp II is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral RF Acquisition Corp II 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NMRA or RFAI?

Neumora Therapeutics presently has a consensus target price of $6.57, indicating a potential upside of 310.71%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60 RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, NMRA or RFAI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Is NMRA or RFAI more profitable?

RF Acquisition Corp II's return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -181.70% -119.15% RF Acquisition Corp II N/A N/A N/A

Does the media refer more to NMRA or RFAI?

In the previous week, Neumora Therapeutics had 1 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 4 mentions for Neumora Therapeutics and 3 mentions for RF Acquisition Corp II. Neumora Therapeutics' average media sentiment score of 1.87 beat RF Acquisition Corp II's score of 1.42 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive RF Acquisition Corp II 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

RF Acquisition Corp II (RFAI) Competitors

$11.08 +0.01 (+0.05%)

As of 04:00 PM Eastern

Compare

RFAI vs. PALI, ZNTL, IKT, VNDA, and NMRA

Should you buy RF Acquisition Corp II stock or one of its competitors? RF Acquisition Corp II's main competitors and comparable companies include Palisade Bio (PALI), Zentalis Pharmaceuticals (ZNTL), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), and Neumora Therapeutics (NMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does RF Acquisition Corp II compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Palisade Bio had 12 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 15 mentions for Palisade Bio and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Palisade Bio's score of 0.48 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RF Acquisition Corp II	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio currently has a consensus target price of $9.00, suggesting a potential upside of 320.56%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

RF Acquisition Corp II's return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.86%	-34.89%
RF Acquisition Corp II	N/A	N/A	N/A

RF Acquisition Corp II has lower revenue, but higher earnings than Palisade Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,491.75	-$16.78M	-$1.01	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

Summary

Palisade Bio beats RF Acquisition Corp II on 7 of the 11 factors compared between the two stocks.

How does RF Acquisition Corp II compare to Zentalis Pharmaceuticals?

RF Acquisition Corp II (NASDAQ:RFAI) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

RF Acquisition Corp II has higher earnings, but lower revenue than Zentalis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
Zentalis Pharmaceuticals	$67.43M	3.78	-$137.06M	-$1.95	N/A

Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 89.61%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Zentalis Pharmaceuticals had 16 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 19 mentions for Zentalis Pharmaceuticals and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Zentalis Pharmaceuticals' score of 0.27 indicating that RF Acquisition Corp II is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RF Acquisition Corp II	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

RF Acquisition Corp II's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
Zentalis Pharmaceuticals	N/A	-64.23%	-48.16%

Summary

Zentalis Pharmaceuticals beats RF Acquisition Corp II on 5 of the 8 factors compared between the two stocks.

How does RF Acquisition Corp II compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 5 mentions for Inhibikase Therapeutics and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Inhibikase Therapeutics' score of -0.02 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RF Acquisition Corp II	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RF Acquisition Corp II has lower revenue, but higher earnings than Inhibikase Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,293.43	-$48.26M	-$0.43	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

RF Acquisition Corp II's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-44.00%	-41.90%
RF Acquisition Corp II	N/A	N/A	N/A

Inhibikase Therapeutics presently has a consensus target price of $5.40, indicating a potential upside of 124.07%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Inhibikase Therapeutics beats RF Acquisition Corp II on 7 of the 11 factors compared between the two stocks.

How does RF Acquisition Corp II compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Vanda Pharmaceuticals currently has a consensus price target of $13.70, indicating a potential upside of 162.45%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Vanda Pharmaceuticals is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vanda Pharmaceuticals had 14 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 17 mentions for Vanda Pharmaceuticals and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Vanda Pharmaceuticals' score of -0.09 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
RF Acquisition Corp II	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RF Acquisition Corp II has lower revenue, but higher earnings than Vanda Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.46	-$220.47M	-$4.63	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

RF Acquisition Corp II has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. RF Acquisition Corp II's return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
RF Acquisition Corp II	N/A	N/A	N/A

Summary

Vanda Pharmaceuticals beats RF Acquisition Corp II on 6 of the 11 factors compared between the two stocks.

How does RF Acquisition Corp II compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

47.7% of Neumora Therapeutics shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Neumora Therapeutics presently has a consensus target price of $6.57, indicating a potential upside of 310.71%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

In the previous week, Neumora Therapeutics had 1 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 4 mentions for Neumora Therapeutics and 3 mentions for RF Acquisition Corp II. Neumora Therapeutics' average media sentiment score of 1.87 beat RF Acquisition Corp II's score of 1.42 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
RF Acquisition Corp II	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RF Acquisition Corp II's return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
RF Acquisition Corp II	N/A	N/A	N/A

Summary

Neumora Therapeutics beats RF Acquisition Corp II on 7 of the 10 factors compared between the two stocks.

Get RF Acquisition Corp II News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RFAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RFAI vs. The Competition

Export

Metric	RF Acquisition Corp II	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$92.37M	$11.73B	$6.98B	$13.04B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	N/A	781.46	269.56	25.30
Price / Sales	N/A	748.39	598.74	101.64
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	N/A	10.80	13.08	6.33
Net Income	N/A	$2.77B	$3.45B	$347.70M
7 Day Performance	0.14%	0.15%	1.11%	1.06%
1 Month Performance	0.05%	0.34%	1.79%	1.03%
1 Year Performance	4.54%	161.53%	67.70%	20.73%

RF Acquisition Corp II Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RFAI RF Acquisition Corp II	1.9508 of 5 stars	$11.08 +0.0%	N/A	+4.6%	$92.37M	N/A	N/A	N/A	News Coverage Positive News Earnings Report Short Interest Decrease
PALI Palisade Bio	3.1645 of 5 stars	$2.11 +1.0%	$9.00 +326.5%	+165.2%	$362.78M	$250K	N/A	10	Earnings Report Analyst Revision
ZNTL Zentalis Pharmaceuticals	2.4653 of 5 stars	$4.22 -15.6%	$6.75 +60.0%	+178.5%	$355.93M	$67.43M	N/A	160	News Coverage Analyst Revision Gap Down
IKT Inhibikase Therapeutics	1.9015 of 5 stars	$2.47 +2.5%	$5.40 +118.6%	N/A	$318.20M	$260K	N/A	6	Earnings Report
VNDA Vanda Pharmaceuticals	2.3566 of 5 stars	$5.00 -2.2%	$14.30 +186.0%	+15.4%	$307.59M	$216.10M	N/A	290	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RFAI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RF Acquisition Corp II (RFAI) Competitors

RFAI vs. PALI, ZNTL, IKT, VNDA, and NMRA

How does RF Acquisition Corp II compare to Palisade Bio?

Summary

How does RF Acquisition Corp II compare to Zentalis Pharmaceuticals?

Summary

How does RF Acquisition Corp II compare to Inhibikase Therapeutics?

Summary

How does RF Acquisition Corp II compare to Vanda Pharmaceuticals?

Summary

How does RF Acquisition Corp II compare to Neumora Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFAI vs. The Competition

RF Acquisition Corp II Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RF Acquisition Corp II (RFAI) Competitors

RFAI vs. PALI, ZNTL, IKT, VNDA, and NMRA

How does RF Acquisition Corp II compare to Palisade Bio?

Do institutionals and insiders hold more shares of PALI or RFAI?

Does the media prefer PALI or RFAI?

Do analysts recommend PALI or RFAI?

Is PALI or RFAI more profitable?

Which has preferable earnings & valuation, PALI or RFAI?

Summary

How does RF Acquisition Corp II compare to Zentalis Pharmaceuticals?

Which has higher earnings and valuation, RFAI or ZNTL?

Do analysts recommend RFAI or ZNTL?

Does the media favor RFAI or ZNTL?

Is RFAI or ZNTL more profitable?

Summary

How does RF Acquisition Corp II compare to Inhibikase Therapeutics?

Does the media prefer IKT or RFAI?

Which has preferable valuation and earnings, IKT or RFAI?

Is IKT or RFAI more profitable?

Do analysts prefer IKT or RFAI?

Do institutionals & insiders believe in IKT or RFAI?

Summary

How does RF Acquisition Corp II compare to Vanda Pharmaceuticals?

Do analysts prefer VNDA or RFAI?

Do institutionals and insiders believe in VNDA or RFAI?

Does the media prefer VNDA or RFAI?

Which has stronger earnings & valuation, VNDA or RFAI?

Is VNDA or RFAI more profitable?

Summary

How does RF Acquisition Corp II compare to Neumora Therapeutics?

Do institutionals & insiders believe in NMRA or RFAI?

Do analysts rate NMRA or RFAI?

Which has stronger valuation and earnings, NMRA or RFAI?

Does the media refer more to NMRA or RFAI?

Is NMRA or RFAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFAI vs. The Competition

RF Acquisition Corp II Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools